No survival benefit by adding chemotherapy to immunotherapy in PD-L1-high NSCLC

Press/Media

Period	Jun 4 2022

Media coverage

Title	No survival benefit by adding chemotherapy to immunotherapy in PD-L1-high NSCLC
Media name/outlet	MedWire News
Country/Territory	United Kingdom
Date	06/4/22
URL	https://www.medwirenews.com/oncology/lung-cancer/no-survival-benefit-chemoimmunotherapy-pd-l1-high-nsclc/23127746
Persons	Sukhmani Kaur Padda